{"symbol": "CFRX", "companyName": "ContraFect Corporation", "exchange": "NASDAQ Capital Market", "industry": "Biotechnology", "website": "http://www.contrafect.com", "description": "ContraFect Corp is a biotechnology company engaged in the development of protein and antibody therapeutic products for life-threatening infectious diseases. The Company's product candidates are CF-301, CF-404.", "CEO": "Steven C. Gilman", "issueType": "cs", "sector": "Healthcare", "tags": ["Healthcare", "Biotechnology"]}